131 related articles for article (PubMed ID: 33435671)
1. Deciphering the T790M/L858R-Selective Inhibition Mechanism of an Allosteric Inhibitor of EGFR: Insights from Molecular Simulations.
Li M; Guo J
ACS Chem Neurosci; 2021 Feb; 12(3):462-472. PubMed ID: 33435671
[TBL] [Abstract][Full Text] [Related]
2. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
3. Insights into the negative regulation of EGFR upon the binding of an allosteric inhibitor.
Li M; Xu Y; Guo J
Chem Biol Drug Des; 2022 Apr; 99(4):650-661. PubMed ID: 35152550
[TBL] [Abstract][Full Text] [Related]
4. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.
To C; Jang J; Chen T; Park E; Mushajiang M; De Clercq DJH; Xu M; Wang S; Cameron MD; Heppner DE; Shin BH; Gero TW; Yang A; Dahlberg SE; Wong KK; Eck MJ; Gray NS; Jänne PA
Cancer Discov; 2019 Jul; 9(7):926-943. PubMed ID: 31092401
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism study of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations.
Wu X; Guo Q; Li Q; Wan S; Li Z; Zhang J
J Biomol Struct Dyn; 2022 Aug; 40(13):5848-5857. PubMed ID: 33459177
[TBL] [Abstract][Full Text] [Related]
6. Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.
Ma Y; Qi B; Ning M; Zhang L; An Z; Zhao J
Eur Biophys J; 2022 Apr; 51(3):283-295. PubMed ID: 35307752
[TBL] [Abstract][Full Text] [Related]
7. Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants.
Saldaña-Rivera L; Bello M; Méndez-Luna D
J Biomol Struct Dyn; 2019 Oct; 37(17):4671-4684. PubMed ID: 30558477
[TBL] [Abstract][Full Text] [Related]
8. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
To C; Beyett TS; Jang J; Feng WW; Bahcall M; Haikala HM; Shin BH; Heppner DE; Rana JK; Leeper BA; Soroko KM; Poitras MJ; Gokhale PC; Kobayashi Y; Wahid K; Kurppa KJ; Gero TW; Cameron MD; Ogino A; Mushajiang M; Xu C; Zhang Y; Scott DA; Eck MJ; Gray NS; Jänne PA
Nat Cancer; 2022 Apr; 3(4):402-417. PubMed ID: 35422503
[TBL] [Abstract][Full Text] [Related]
9. Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations.
Jang J; To C; De Clercq DJH; Park E; Ponthier CM; Shin BH; Mushajiang M; Nowak RP; Fischer ES; Eck MJ; Jänne PA; Gray NS
Angew Chem Int Ed Engl; 2020 Aug; 59(34):14481-14489. PubMed ID: 32510788
[TBL] [Abstract][Full Text] [Related]
10. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
11. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
[TBL] [Abstract][Full Text] [Related]
12. Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor.
Yang Z; Yang H; Ai Y; Zhang L; Li Z; Wan S; Xu X; Zhang H; Wu S; Zhang J; Zhang T
Eur J Pharm Sci; 2020 Sep; 152():105463. PubMed ID: 32668314
[TBL] [Abstract][Full Text] [Related]
13. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
Patel H; Pawara R; Surana S
Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
[TBL] [Abstract][Full Text] [Related]
14. Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking.
Caporuscio F; Tinivella A; Restelli V; Semrau MS; Pinzi L; Storici P; Broggini M; Rastelli G
Future Med Chem; 2018 Jul; 10(13):1545-1553. PubMed ID: 29766737
[TBL] [Abstract][Full Text] [Related]
15. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
16. Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
Günther M; Lategahn J; Juchum M; Döring E; Keul M; Engel J; Tumbrink HL; Rauh D; Laufer S
J Med Chem; 2017 Jul; 60(13):5613-5637. PubMed ID: 28603991
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor.
Pratama MRF; Poerwono H; Siswodihardjo S
J Basic Clin Physiol Pharmacol; 2019 Dec; 30(6):. PubMed ID: 31855568
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.
Hu C; Wang A; Wu H; Qi Z; Li X; Yan XE; Chen C; Yu K; Zou F; Wang W; Wang W; Wu J; Liu J; Wang B; Wang L; Ren T; Zhang S; Yun CH; Liu J; Liu Q
Oncotarget; 2017 Mar; 8(11):18359-18372. PubMed ID: 28407693
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites.
Fan M; Hu L; Shi S; Song X; He H; Qi B
Bioorg Med Chem; 2023 Dec; 96():117534. PubMed ID: 37952262
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]